The Translation Failure: Why Good Science Is Not Enough
I have watched promising life sciences companies fail for reasons that had surprisingly little to do with the quality of their science.
The technology was compelling. The clinical rationale was defensible. The unmet medical need was real.
Yet the company struggled to raise capital, secure a strategic partner, or convince its board to stay the course.
What went wrong?
Often, it was a translation failure.
The leadership understood the science. The investors understood the capital. Neither adequately understood the other’s decision-making framework.
That disconnect matters more than most founders and CEOs appreciate.
Why Translation Matters
In life sciences, scientific merit does not automatically translate into investment value.
A promising clinical result means one thing to a scientist evaluating biological activity. It means something different to an investor evaluating probability of success, capital requirements, competitive positioning, and expected returns.
Neither perspective is inherently wrong. Both are necessary.
The problem arises when leaders cannot connect them.
I have seen scientist-founders defend their data when investors were questioning capital efficiency. I have seen financial professionals focus on valuation while overlooking critical clinical development risks. And I have seen boards make consequential decisions without fully understanding the science or the financial implications.
These are not simply communication problems. They are failures of judgment that can destroy shareholder value and derail otherwise promising programs.
What Leaders Need to Understand
The central argument of Chapter 1 of my book, Dual Fluency, is straightforward.
Knowing your science is not the same as knowing how to finance, develop, and commercialize it.
Likewise, understanding financial markets does not necessarily qualify someone to evaluate clinical risk or scientific probability.
Dual Fluency requires both.
For founders and CEOs, that means understanding how scientific uncertainty influences valuation, financing strategy, and investor decisions.
For investors and board directors, it means understanding how clinical evidence, regulatory requirements, and development risks influence the allocation of capital.
The goal is not to become an expert in everything. It is to develop enough fluency in both disciplines to recognize what matters, ask better questions, and make better decisions.
The Real Cost of Getting It Wrong
A failed translation can cost a company a financing round, a partnership, or years of development.
But the consequences extend beyond shareholders and employees.
When a promising program is abandoned for the wrong reasons, patients may lose access to a potentially meaningful innovation.
Not every scientific hypothesis deserves continued funding. Knowing when to stop is as important as knowing when to advance.
The challenge is ensuring those decisions are made with a complete understanding of both the science and the economics.
Great science does not guarantee success. Great leadership gives it a better chance.
That is why understanding the translation failure matters.
And that is where Dual Fluency begins.
This blog article introduces Chapter 1, “The Translation Failure,” from the book, Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital.
I welcome your perspective. Have you witnessed a promising company lose investor support because the leadership could not effectively translate its scientific opportunity into an investment proposition?
David H. Crean, PhD, MBA
Author, Dual Fluency